arrow
P

Patrick Dallemagne

normandie univ
H指数:32
被引数:4,114

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Design, synthesis and biological evaluation of pleiotropic prodrugs activated by cholinesterases and releasing a 5-HT4R agonist, with in vivo antiamnesic activity.

设计、合成及生物学评价:经胆碱酯酶激活并释放5-HT<sub>4</sub>R激动剂、具有体内抗遗忘活性的多效前药

2026-10-100
OAAI
Enhancing brain delivery of tegaserod for Alzheimer’s disease: a pharmaceutical comparison of two nanocarrier-based strategies

增强替加色罗在阿尔茨海默病中的脑内递送:两种基于纳米载体的策略的药物学比较

2026-07-150
OAAI
Rational Design and Evaluation of Rivastigmine-Based Pleiotropic Prodrugs for the Treatment of Alzheimer’s Disease

基于利伐斯明(Rivastigmine)的多效性前药的设计与评估:用于治疗阿尔茨海默病

2026-04-130
PRE
Polyfunctionalized N-Arylsulfonyl Indoles: Identification of (E)-N-Hydroxy-3-{3-[(5-(3-(piperidin-1-yl)propoxy]-1H-indol-1-yl)sulfonyl]phenyl}acrylamide (MTP150) for the Epigenetic-based Therapy of Parkinson’s Disease

多官能化N-芳基磺酰基吲哚:用于表观遗传学基础治疗帕金森病的(E)-N-羟基-3-{3-[(5-(3-(哌啶-1-基)丙氧基)-1H-吲哚-1-基)磺酰基]苯基}丙烯酰胺(MTP150)的鉴定

2026-03-310
OAAI
An efficient step-by-step approach to select pleiotropic drug candidates against Alzheimer's disease: The discovery of neocopride

一种高效、分步筛选针对阿尔茨海默病的多效性药物候选物的方法:neocopride的发现

2026-03-130
PRE
Access to novel potent pleiotropic prodrugs, targeting both butyrylcholinesterase and serotonin reuptake, with anti-amnesic activities in Alzheimer’s disease model.

获得新型强效多效性前药,其靶向丁酰胆碱酯酶和血清素再摄取,并在阿尔茨海默病模型中具有抗遗忘活性。

2026-02-120
PRE
Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound

预防神经病变并改善以咔唑为基团的化合物抗癌化疗

2025-10-290
PRE
Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer's disease by administration through an intranasal route

来自小鼠模型的证据支持通过鼻内途径给药将抗哮喘药物bambuterol重新用于治疗阿尔茨海默氏病

2025-02-010
OAAI
Synthesis, in vitro and in vivo biological evaluation of novel dual compounds targeting both acetylcholinesterase and serotonergic 5-HT4 receptors with potential interest in the treatment of Alzheimer's disease
2024-12-010
OAAI
Dynamic microfluidic single-cell screening identifies pheno-tuning compounds to potentiate tuberculosis therapy
2024-05-161
OAAI